Centessa Pharmaceuticals plc
CNTANasdaqHealthcare · Pharmaceutical Preparations · X0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $15.0M | $0 | $6.9M | $0 | — | — |
| Operating income | −$207.7M | −$201.1M | −$171.3M | −$212.3M | −$783,000 | −$10.4M |
| Net income | −$197.5M | −$235.8M | −$151.1M | −$216.2M | −$829,000 | −$10.7M |
| Total assets | $687.5M | $576.8M | $360.2M | $444.3M | $629.6M | $11.7M |
| Total liabilities | $160.6M | $175.3M | $124.0M | $108.1M | $138.1M | $8.6M |
| Equity | $526.9M | $401.5M | $236.2M | $336.2M | $491.6M | — |
| EPS (diluted) | $-1.46 | $-2.06 | $-1.57 | $-2.31 | $-5.07 | — |
| Shares out. | 133.2M | 100.3M | 95.0M | 94.0M | 90.0M | 0 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1384.6%
- Net margin
- −1316.9%
- Return on equity
- −37.5%
- Return on assets
- −28.7%
- Return on capital (ROCE)
- −32.2%
- Liabilities / assets
- 23.4%
- Debt / equity
- 0.30×
- Book value / share
- $3.96
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.11distress
- Accruals / assets
- −0.5%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-04-30A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Phase 1Recruitingreadout ~2026-06-15A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
- Phase 2Recruitingreadout ~2026-12A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Phase 1Recruitingreadout ~2027-06-30A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
- Phase 2/3Not Yet Recruitingreadout ~2027-09-30A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Pentwater Capital Management LpPassive (13G)May 15, 2026
- Avoro Capital Advisors LlcPassive (13G)May 15, 2026
- Adage Capital Management, L.P.Passive (13G)May 13, 2026
- Fmr LlcPassive (13G)May 6, 2026
- General Atlantic Cooperatief U.A.Activist (13D)Nov 28, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Accardi Mario AlbertoOfficer — Chief Executive Officer | May 1, 2026 | Tax withholding | 604 | $39.42 |
| Anderson Karen M.Officer — Chief People Officer | Mar 26, 2026 | Option exercise | 41,076 | $8.01 |
| Weinhoff Gregory MOfficer — Chief Business Officer | Mar 26, 2026 | Option exercise | 23,998 | $3.85 |
| Anderson Karen M.Officer — Chief People Officer | Mar 16, 2026 | Option exercise | 64,768 | $4.01 |
| Anderson Karen M.Officer — Chief People Officer | Mar 13, 2026 | Option exercise | 109,398 | $4.01 |
| Weinhoff Gregory MOfficer — Chief Business Officer | Mar 13, 2026 | Sell | 61,253 | $26.17 |
| Kanes StephenOfficer — Chief Medical Officer | Feb 2, 2026 | Grant | 120,000 | $0.00 |
| Crowley John JOfficer — Chief Financial Officer | Feb 2, 2026 | Grant | 45,000 | $0.00 |
| Deferiere RaphaelOfficer — Chief Accounting Officer | Feb 2, 2026 | Grant | 11,000 | $0.00 |
| Hussain Iqbal JOfficer — Chief Legal Officer | Jan 30, 2026 | Sell | 1,010 | $25.01 |
| Weinhoff Gregory MOfficer — Chief Business Officer | Feb 1, 2026 | Tax withholding | 14,158 | $24.57 |
| Accardi Mario AlbertoOfficer — Chief Executive Officer | Feb 1, 2026 | Tax withholding | 2,915 | $24.57 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.5M | 2.3 | -11.8% |
| Apr 30, 2026 | 2.8M | 1.2 | -19.3% |
| Apr 15, 2026 | 3.5M | 1.0 | -47.5% |
| Mar 31, 2026 | 6.6M | 1.3 | -0.1% |
| Mar 13, 2026 | 6.6M | 4.7 | +5.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 22, 2026
- Entered a material agreement · Regulation FD disclosureMar 31, 2026
- Director / officer changeFeb 13, 2026
- Director / officer change · Regulation FD disclosureDec 11, 2025
- Other material eventNov 24, 2025
- Entered a material agreement · Other material eventNov 13, 2025
- Results of operations · Regulation FD disclosureNov 5, 2025
- Results of operationsAug 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 22, 2026
- 4FORM 4May 18, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 13, 2026
- DEFM14AMay 7, 2026
- SCHEDULE 13G/AMay 6, 2026
- 10-QMay 5, 2026
- ARSApr 29, 2026
- DEF 14AApr 29, 2026
- PREM14AApr 17, 2026
- DEFA14AApr 13, 2026
- DEFA14AMar 31, 2026
- DEFA14AMar 31, 2026
- DEFA14AMar 31, 2026